Phase 3 interim analysis of Oxford Vaccine including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens
In the two different dose regimens vaccine efficacy was 90% in one and 62% in the other.
Early indication that vaccine could reduce virus transmission from an observed reduction in asymptomatic infections
There were no hospitalised or severe cases in anyone who received the vaccine
Large safety database from over 24,000 volunteers from clinical trials in the UK, Brazil and South Africa, with follow up since April.
Crucially, vaccine can be easily administered in existing healthcare systems, stored at ‘fridge temperature’ (2-8 °C) and distributed using existing logistics.
Large scale manufacturing ongoing in over 10 countries to support equitable global access
